These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38405079)

  • 21. Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease.
    Shehadeh J; Double KL; Murphy KE; Bobrovskaya L; Reyes S; Dunkley PR; Halliday GM; Dickson PW
    Neurobiol Dis; 2019 Oct; 130():104524. PubMed ID: 31276794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
    Korecka JA; Eggers R; Swaab DF; Bossers K; Verhaagen J
    Restor Neurol Neurosci; 2013; 31(2):155-67. PubMed ID: 23271419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
    McCormack AL; Thiruchelvam M; Manning-Bog AB; Thiffault C; Langston JW; Cory-Slechta DA; Di Monte DA
    Neurobiol Dis; 2002 Jul; 10(2):119-27. PubMed ID: 12127150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of dopaminergic neuronal dysfunction in genetic and toxin-induced models of Parkinson's disease in Drosophila.
    Navarro JA; Heßner S; Yenisetti SC; Bayersdorfer F; Zhang L; Voigt A; Schneuwly S; Botella JA
    J Neurochem; 2014 Nov; 131(3):369-82. PubMed ID: 25040725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopaminergic but not cholinergic neurodegeneration is correlated with gait disturbances in PINK1 knockout rats.
    DeAngelo VM; Hilliard JD; McConnell GC
    Behav Brain Res; 2022 Jan; 417():113575. PubMed ID: 34534596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuronal activity regulates expression of tyrosine hydroxylase in adult mouse substantia nigra pars compacta neurons.
    Aumann TD; Egan K; Lim J; Boon WC; Bye CR; Chua HK; Baban N; Parish CL; Bobrovskaya L; Dickson P; Horne MK
    J Neurochem; 2011 Feb; 116(4):646-58. PubMed ID: 21166807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
    Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
    Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olfactory Bulb Excitotoxicity as a Gap-Filling Mechanism Underlying the Link Between Traumatic Brain Injury-Induced Secondary Neuronal Degeneration and Parkinson's Disease-Like Pathology.
    Marin C; Fuentes M; Alobid I; Tubita V; Rojas-Lechuga MJ; Mullol J
    Neurochem Res; 2022 Apr; 47(4):1025-1036. PubMed ID: 35067829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine receptor activation mitigates mitochondrial dysfunction and oxidative stress to enhance dopaminergic neurogenesis in 6-OHDA lesioned rats: A role of Wnt signalling.
    Mishra A; Singh S; Tiwari V; Chaturvedi S; Wahajuddin M; Shukla S
    Neurochem Int; 2019 Oct; 129():104463. PubMed ID: 31078578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.
    Watts PM; Riedl AG; Douek DC; Edwards RJ; Boobis AR; Jenner P; Marsden CD
    Neuroscience; 1998 Sep; 86(2):511-9. PubMed ID: 9881865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
    Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
    Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.
    Pedersen V; Schmidt WJ
    Neurotox Res; 2000; 2(2-3):179-204. PubMed ID: 16787840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta.
    Sarbazi-Golezari A; Haghdoost-Yazdi H
    Metab Brain Dis; 2022 Feb; 37(2):373-381. PubMed ID: 34767157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.
    Zhang J; Sun B; Yang J; Chen Z; Li Z; Zhang N; Li H; Shen L
    Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35039876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neonatal 6-OHDA lesion of the SNc induces striatal compensatory sprouting from surviving SNc dopaminergic neurons without VTA contribution.
    Tanguay W; Ducrot C; Giguère N; Bourque MJ; Trudeau LE
    Eur J Neurosci; 2021 Oct; 54(7):6618-6632. PubMed ID: 34470083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values.
    Liu LX; Du D; Zheng T; Fang Y; Chen YS; Yi HL; He QY; Gao DW; Shi QL
    Neural Regen Res; 2017 Sep; 12(9):1485-1491. PubMed ID: 29089995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
    Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.